2022 연구성과별 연구자 정보 (58 / 2879)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli | Biruhanu, Biruk Tesfaye | Biruhanu, BT | 4 | 교신저자 | Kyungpook Natl Univ, Cardiovasc Inst, Coll Vet Med, Lab Vet Pharmacokinet & Pharmacodynam, Daegu, Gyeongsangbugdo, South Korea | btbtes@gmail.com;parksch@knu.ac.kr; | ||||
| A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli | Park, Seung-Chun | Park, SC | 5 | 교신저자 | Kyungpook Natl Univ, Cardiovasc Inst, Coll Vet Med, Lab Vet Pharmacokinet & Pharmacodynam, Daegu, Gyeongsangbugdo, South Korea | AAV-3388-2021 | Park, Seung-Chun | btbtes@gmail.com;parksch@knu.ac.kr; | ||
| A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli | Park, Seung-Chun | Park, SC | 5 | 교신저자 | Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Daegu, Gyeongsangbugdo, South Korea | AAV-3388-2021 | Park, Seung-Chun | btbtes@gmail.com;parksch@knu.ac.kr; | ||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Daver, Naval | Daver, N | 1 | Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA | AFU-9643-2022 | Daver, Naval | ||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Lee, Kyoo Hyung | Lee, KH | 2 | Univ Ulsan, Coll Med, Dept Hematol, Asan Med Ctr, Seoul, South Korea | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Jonas, Brian A. | Jonas, BA | 3 | Univ Calif Davis, Dept Internal Med, Div Cellular Therapy Bone Marrow Transplantat & M, Sch Med, Sacramento, CA USA | AAS-3639-2020 | Jonas, Brian | ||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Arellano, Martha L. | Arellano, ML | 4 | Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA USA | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Jung, Chul W. | Jung, CW | 5 | Samsung Med Ctr, Seoul, South Korea | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Sohn, Sang Kyun | Sohn, SK | 6 | Kyungpook Natl Univ Hosp, Daegu, South Korea | HJA-3755-2022 | Park, Jung Hyun | ||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Yoon, Sung-Soo | Yoon, SS | 7 | Seoul Natl Univ Hosp, Dept Internal Med, Div Hematol Med Oncol, Seoul, South Korea | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Lee, Jeong-Ok | Lee, JO | 8 | Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematooncol, Seongnam, South Korea | J-5603-2012 | Lee, Jong-Seok | ||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Hu, Jia | Hu, J | 9 | Aptose Biosci Inc, San Diego, CA USA | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Sinha, Ranjeet Kumar | Sinha, RK | 10 | Aptose Biosci Inc, San Diego, CA USA | D-4427-2014 | Sinha, Ranjeet | ||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Rice, William G. | Rice, WG | 11 | Aptose Biosci Inc, San Diego, CA USA | ||||||
| A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Bejar, Rafael | Bejar, R | 12 | Aptose Biosci Inc, San Diego, CA USA |
페이지 이동: